메뉴 건너뛰기




Volumn 38, Issue 6, 2012, Pages 787-797

Therapeutic approaches to myeloma bone disease: An evolving story

Author keywords

Multiple myeloma; Myeloma bone disease; Osteoblasts; Osteoclasts; Osteolyses; Skeletal related events

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; ATACICEPT; AZDZ 6244; B CELL ACTIVATING FACTOR; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DASATINIB; DENOSUMAB; DICKKOPF 1 PROTEIN; ETARACIZUMAB; ETIDRONIC ACID; LY 2228820; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MLN 3897; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PIMASERTIB; RAP 011; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SELUMETINIB; SNX 2112; SOTATERCEPT; TABALUMAB; TALABOSTAT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

EID: 84861705343     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.004     Document Type: Review
Times cited : (21)

References (161)
  • 1
    • 80051580618 scopus 로고    scopus 로고
    • Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
    • Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
    • (2011) CA Cancer J Clin , vol.61 , Issue.4 , pp. 212-236
    • Siegel, R.1    Ward, E.2    Brawley, O.3    Jemal, A.4
  • 4
    • 0035010803 scopus 로고    scopus 로고
    • Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    • Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176.
    • (2001) Cancer Treat Rev , vol.27 , Issue.3 , pp. 165-176
    • Coleman, R.E.1
  • 5
    • 34249087771 scopus 로고    scopus 로고
    • Economic burden of metastatic bone disease in the U.S
    • Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007, 109(11):2334-2342.
    • (2007) Cancer , vol.109 , Issue.11 , pp. 2334-2342
    • Schulman, K.L.1    Kohles, J.2
  • 6
    • 1542330894 scopus 로고    scopus 로고
    • Pathogenesis of myeloma bone disease
    • Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004, 32:290-292.
    • (2004) Blood Cells Mol Dis , vol.32 , pp. 290-292
    • Roodman, G.D.1
  • 7
    • 78650417743 scopus 로고    scopus 로고
    • Osteoblast function in myeloma
    • Roodman G.D. Osteoblast function in myeloma. Bone 2011, 48(1):135-140.
    • (2011) Bone , vol.48 , Issue.1 , pp. 135-140
    • Roodman, G.D.1
  • 8
    • 76349110797 scopus 로고    scopus 로고
    • Osteoblastogenesis and tumor growth in myeloma
    • Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010, 51:213-220.
    • (2010) Leuk Lymphoma , vol.51 , pp. 213-220
    • Yaccoby, S.1
  • 9
    • 63549123413 scopus 로고    scopus 로고
    • The role of bisphosphonates in multiple myeloma
    • Levy J., Roodman G.D. The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 2009, 4(2):108-112.
    • (2009) Curr Hematol Malig Rep , vol.4 , Issue.2 , pp. 108-112
    • Levy, J.1    Roodman, G.D.2
  • 10
    • 0025916366 scopus 로고
    • Effect of daily etidronate on the osteolysis of multiple myeloma
    • Belch A.R., Bergsagel D.E., Wilson K., et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9(8):1397-1402.
    • (1991) J Clin Oncol , vol.9 , Issue.8 , pp. 1397-1402
    • Belch, A.R.1    Bergsagel, D.E.2    Wilson, K.3
  • 11
    • 0026646339 scopus 로고
    • Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group
    • Lahtinen R., Laakso M., Palva I., Virkkunen P., Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992, 340(8827):1049-1052.
    • (1992) Lancet , vol.340 , Issue.8827 , pp. 1049-1052
    • Lahtinen, R.1    Laakso, M.2    Palva, I.3    Virkkunen, P.4    Elomaa, I.5
  • 12
    • 6844252283 scopus 로고    scopus 로고
    • Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group
    • Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16(2):593-602.
    • (1998) J Clin Oncol , vol.16 , Issue.2 , pp. 593-602
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 13
    • 10744233021 scopus 로고    scopus 로고
    • Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
    • Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8):1735-1744.
    • (2003) Cancer , vol.98 , Issue.8 , pp. 1735-1744
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 14
    • 84861666016 scopus 로고    scopus 로고
    • Bisphosphonates as antimyeloma drugs
    • Modi N.D., Lentzsch S. Bisphosphonates as antimyeloma drugs. Leukemia 2011, 18.
    • (2011) Leukemia , pp. 18
    • Modi, N.D.1    Lentzsch, S.2
  • 15
    • 47549113482 scopus 로고    scopus 로고
    • Clodronate inhibits angiogenesis in vitro and in vivo
    • Ribatti D., Maruotti N., Nico B., et al. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep 2008, 19(5):1109-1112.
    • (2008) Oncol Rep , vol.19 , Issue.5 , pp. 1109-1112
    • Ribatti, D.1    Maruotti, N.2    Nico, B.3
  • 16
    • 34249877405 scopus 로고    scopus 로고
    • Neridronate inhibits angiogenesis in vitro and in vivo
    • Ribatti D., Nico B., Mangieri D., et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 2007, 26(7):1094-1098.
    • (2007) Clin Rheumatol , vol.26 , Issue.7 , pp. 1094-1098
    • Ribatti, D.1    Nico, B.2    Mangieri, D.3
  • 17
    • 78650174738 scopus 로고    scopus 로고
    • First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
    • Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
    • (2010) Lancet , vol.376 , pp. 1989-1999
    • Morgan, G.J.1    Davies, F.E.2    Gregory, W.M.3
  • 18
    • 56749105613 scopus 로고    scopus 로고
    • New developments surrounding the safety of bisphosphonates
    • Arum S.M. New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes 2008, 15:508-513.
    • (2008) Curr Opin Endocrinol Diabetes Obes , vol.15 , pp. 508-513
    • Arum, S.M.1
  • 19
    • 10744228141 scopus 로고    scopus 로고
    • Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
    • Markowitz G.S., Fine P.L., Stack J.I., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003, 64(1):281-289.
    • (2003) Kidney Int , vol.64 , Issue.1 , pp. 281-289
    • Markowitz, G.S.1    Fine, P.L.2    Stack, J.I.3
  • 20
    • 0035007762 scopus 로고    scopus 로고
    • Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate
    • Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001, 12(6):1164-1172.
    • (2001) J Am Soc Nephrol , vol.12 , Issue.6 , pp. 1164-1172
    • Markowitz, G.S.1    Appel, G.B.2    Fine, P.L.3
  • 21
    • 1642439058 scopus 로고    scopus 로고
    • Podocyte injury associated glomerulopathies induced by pamidronate
    • Barri Y.M., Munshi N.C., Sukumalchantra S., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004, 65(2):634-641.
    • (2004) Kidney Int , vol.65 , Issue.2 , pp. 634-641
    • Barri, Y.M.1    Munshi, N.C.2    Sukumalchantra, S.3
  • 22
    • 70349234673 scopus 로고    scopus 로고
    • Pamidronate-induced kidney injury in a patient with metastatic breast cancer
    • Nagahama M., Sica D.A. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci 2009, 338(3):225-228.
    • (2009) Am J Med Sci , vol.338 , Issue.3 , pp. 225-228
    • Nagahama, M.1    Sica, D.A.2
  • 23
    • 33644906138 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
    • Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24:945-952.
    • (2006) J Clin Oncol , vol.24 , pp. 945-952
    • Badros, A.1    Weikel, D.2    Salama, A.3
  • 24
    • 34250313823 scopus 로고    scopus 로고
    • A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patient with multiple myeloma
    • Corso A., Varettoni M., Zappasodi P., et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patient with multiple myeloma. Leukemia 2007, 21(7):1545-1548.
    • (2007) Leukemia , vol.21 , Issue.7 , pp. 1545-1548
    • Corso, A.1    Varettoni, M.2    Zappasodi, P.3
  • 25
    • 78650307647 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review
    • Migliorati C.A., Epstein J.B., Abt E., Berenson J.R. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011, 7(1):34-42.
    • (2011) Nat Rev Endocrinol , vol.7 , Issue.1 , pp. 34-42
    • Migliorati, C.A.1    Epstein, J.B.2    Abt, E.3    Berenson, J.R.4
  • 26
    • 44649143245 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid
    • Cafro A.M., Barbarano L., Nosari A.M., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 2008, 8(2):111-116.
    • (2008) Clin Lymphoma Myeloma , vol.8 , Issue.2 , pp. 111-116
    • Cafro, A.M.1    Barbarano, L.2    Nosari, A.M.3
  • 27
    • 54049124120 scopus 로고    scopus 로고
    • GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
    • Musto P., Petrucci M.T., Bringhen S., et al. GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008, 113(7):1588-1595.
    • (2008) Cancer , vol.113 , Issue.7 , pp. 1588-1595
    • Musto, P.1    Petrucci, M.T.2    Bringhen, S.3
  • 28
    • 55649090798 scopus 로고    scopus 로고
    • Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate
    • Walter C., Al-Nawas B., Grötz K.A., et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008, 54(5):1066-1072.
    • (2008) Eur Urol , vol.54 , Issue.5 , pp. 1066-1072
    • Walter, C.1    Al-Nawas, B.2    Grötz, K.A.3
  • 29
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    • Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822.
    • (2011) Lancet , vol.377 , Issue.9768 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3
  • 30
    • 79959565208 scopus 로고    scopus 로고
    • Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    • Gnant M., Mlineritsch B., Stoeger H., et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12(7):631-641.
    • (2011) Lancet Oncol , vol.12 , Issue.7 , pp. 631-641
    • Gnant, M.1    Mlineritsch, B.2    Stoeger, H.3
  • 31
    • 73849148160 scopus 로고    scopus 로고
    • Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw
    • Vahtsevanos K., Kyrgidis A., Verrou E., et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009, 27(32):5356-5362.
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5356-5362
    • Vahtsevanos, K.1    Kyrgidis, A.2    Verrou, E.3
  • 32
    • 77956471761 scopus 로고    scopus 로고
    • Bisphosphonate osteonecrosis section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer
    • Migliorati C.A., Woo S.B., Hewson I., et al. Bisphosphonate osteonecrosis section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010, 18(8):1099-1106.
    • (2010) Support Care Cancer , vol.18 , Issue.8 , pp. 1099-1106
    • Migliorati, C.A.1    Woo, S.B.2    Hewson, I.3
  • 33
    • 77956463416 scopus 로고    scopus 로고
    • Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature
    • Brennan M.T., Elting L.S., Spijkervet F.K. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer 2010, 18(8):979-984.
    • (2010) Support Care Cancer , vol.18 , Issue.8 , pp. 979-984
    • Brennan, M.T.1    Elting, L.S.2    Spijkervet, F.K.3
  • 34
    • 77952646938 scopus 로고    scopus 로고
    • Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review
    • Weide R., Koppler H., Antras L., et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 2010, 6(1):31-35.
    • (2010) J Cancer Res Ther , vol.6 , Issue.1 , pp. 31-35
    • Weide, R.1    Koppler, H.2    Antras, L.3
  • 35
    • 33947270358 scopus 로고    scopus 로고
    • The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    • Oh W.K., Proctor K., Nakabayashi M., et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007 Mar 15, 109(6):1090-1096.
    • (2007) Cancer , vol.109 , Issue.6 , pp. 1090-1096
    • Oh, W.K.1    Proctor, K.2    Nakabayashi, M.3
  • 36
    • 34249884844 scopus 로고    scopus 로고
    • The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy
    • Israeli R.S., Rosenberg S.J., Saltzstein D.R., et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5(4):271-277.
    • (2007) Clin Genitourin Cancer , vol.5 , Issue.4 , pp. 271-277
    • Israeli, R.S.1    Rosenberg, S.J.2    Saltzstein, D.R.3
  • 37
    • 77149169463 scopus 로고    scopus 로고
    • Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study
    • Houston S., Grieve R.J., Hickish T., Percival F., Hamilton E. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. J Med Econ 2010, 13(1):162-167.
    • (2010) J Med Econ , vol.13 , Issue.1 , pp. 162-167
    • Houston, S.1    Grieve, R.J.2    Hickish, T.3    Percival, F.4    Hamilton, E.5
  • 38
    • 33646863929 scopus 로고    scopus 로고
    • Management of the adverse effects associated with intravenous bisphosphonates
    • Tanvetyanon T., Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006, 17(6):897-907.
    • (2006) Ann Oncol , vol.17 , Issue.6 , pp. 897-907
    • Tanvetyanon, T.1    Stiff, P.J.2
  • 39
    • 33847623326 scopus 로고    scopus 로고
    • Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
    • Aguiar Bujanda D., Bohn Sarmiento U., Cabrera Suárez M.A., Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007, 18(3):556-560.
    • (2007) Ann Oncol , vol.18 , Issue.3 , pp. 556-560
    • Aguiar Bujanda, D.1    Bohn Sarmiento, U.2    Cabrera Suárez, M.A.3    Aguiar Morales, J.4
  • 40
    • 69449108135 scopus 로고    scopus 로고
    • The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
    • Terpos E., Sezer O., Croucher P.I., et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009, 20:1303-1317.
    • (2009) Ann Oncol , vol.20 , pp. 1303-1317
    • Terpos, E.1    Sezer, O.2    Croucher, P.I.3
  • 41
    • 34347260332 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
    • Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25(17):2464-2472.
    • (2007) J Clin Oncol , vol.25 , Issue.17 , pp. 2464-2472
    • Kyle, R.A.1    Yee, G.C.2    Somerfield, M.R.3
  • 42
    • 84861691454 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma
    • Fort Washington, PA: National Comprehensive Cancer Network Inc., 2011.
    • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. vol. 1. 2012. Fort Washington, PA: National Comprehensive Cancer Network Inc., 2011.
    • (2012) , vol.1
  • 43
    • 79952721484 scopus 로고    scopus 로고
    • Advances in the biology and treatment of bone disease in multiple myeloma
    • Raje N., Roodman G.D. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011, 17(6):1278-1286.
    • (2011) Clin Cancer Res , vol.17 , Issue.6 , pp. 1278-1286
    • Raje, N.1    Roodman, G.D.2
  • 44
    • 58249101211 scopus 로고    scopus 로고
    • Bone marrow microenvironment and the identification of new targets for myeloma therapy
    • Podar K., Chauhan D., Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24.
    • (2009) Leukemia , vol.23 , pp. 10-24
    • Podar, K.1    Chauhan, D.2    Anderson, K.C.3
  • 45
    • 0032584208 scopus 로고    scopus 로고
    • Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    • Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 3597-3602
    • Yasuda, H.1    Shima, N.2    Nakagawa, N.3
  • 46
    • 0035949510 scopus 로고    scopus 로고
    • Multiple Myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
    • Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple Myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001, 98:11581-11586.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 11581-11586
    • Pearse, R.N.1    Sordillo, E.M.2    Yaccoby, S.3
  • 47
    • 0037443533 scopus 로고    scopus 로고
    • RANK ligand and osteoprotegerin in myeloma bone disease
    • Sezer O., Heider U., Zavrski I., Kühne C.A., Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101:2094-2098.
    • (2003) Blood , vol.101 , pp. 2094-2098
    • Sezer, O.1    Heider, U.2    Zavrski, I.3    Kühne, C.A.4    Hofbauer, L.C.5
  • 48
    • 0031869001 scopus 로고    scopus 로고
    • Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis
    • Hofbauer L.C., Heufelder A.E. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998, 139:152-154.
    • (1998) Eur J Endocrinol , vol.139 , pp. 152-154
    • Hofbauer, L.C.1    Heufelder, A.E.2
  • 49
    • 0043245842 scopus 로고    scopus 로고
    • Soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
    • Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappa B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102:1064-1069.
    • (2003) Blood , vol.102 , pp. 1064-1069
    • Terpos, E.1    Szydlo, R.2    Apperley, J.F.3
  • 50
    • 58649113384 scopus 로고    scopus 로고
    • Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL
    • Kostenuik P.J., Nguyen H.Q., McCabe J., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
    • (2009) J Bone Miner Res , vol.24 , pp. 182-195
    • Kostenuik, P.J.1    Nguyen, H.Q.2    McCabe, J.3
  • 51
    • 27744529640 scopus 로고    scopus 로고
    • Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
    • Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005, 5:618-625.
    • (2005) Curr Opin Pharmacol , vol.5 , pp. 618-625
    • Kostenuik, P.J.1
  • 53
    • 79952761418 scopus 로고    scopus 로고
    • Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    • Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29(9):1125-1132.
    • (2011) J Clin Oncol , vol.29 , Issue.9 , pp. 1125-1132
    • Henry, D.H.1    Costa, L.2    Goldwasser, F.3
  • 54
    • 72849114497 scopus 로고    scopus 로고
    • Denosumab: the era of targeted therapies in bone metastatic diseases
    • Santini D., Fratto M.E., Vincenzi B., et al. Denosumab: the era of targeted therapies in bone metastatic diseases. Curr Cancer Drug Targets 2009, 9(7):834-842.
    • (2009) Curr Cancer Drug Targets , vol.9 , Issue.7 , pp. 834-842
    • Santini, D.1    Fratto, M.E.2    Vincenzi, B.3
  • 55
    • 0942298590 scopus 로고    scopus 로고
    • Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
    • Novak A.J., Darce J.R., Arendt B.K., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103(2):689-694.
    • (2004) Blood , vol.103 , Issue.2 , pp. 689-694
    • Novak, A.J.1    Darce, J.R.2    Arendt, B.K.3
  • 56
    • 11144355586 scopus 로고    scopus 로고
    • BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
    • Moreaux J., Legouffe E., Jourdan E., et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004, 103(8):3148-3157.
    • (2004) Blood , vol.103 , Issue.8 , pp. 3148-3157
    • Moreaux, J.1    Legouffe, E.2    Jourdan, E.3
  • 57
    • 33746122751 scopus 로고    scopus 로고
    • Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
    • Tai Y.T., Li X.F., Breitkreutz I., et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006, 66(13):6675-6682.
    • (2006) Cancer Res , vol.66 , Issue.13 , pp. 6675-6682
    • Tai, Y.T.1    Li, X.F.2    Breitkreutz, I.3
  • 58
    • 35348915408 scopus 로고    scopus 로고
    • Neutralizing Bcell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model
    • Neri P., Kumar S., Fulciniti M.T., et al. Neutralizing Bcell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007, 13(19):5903-5909.
    • (2007) Clin Cancer Res , vol.13 , Issue.19 , pp. 5903-5909
    • Neri, P.1    Kumar, S.2    Fulciniti, M.T.3
  • 59
    • 84861714289 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/study/NCT00689507.
  • 60
    • 79953684902 scopus 로고    scopus 로고
    • Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia
    • Rossi J.F. Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011, 11(1):136-138.
    • (2011) Clin Lymphoma Myeloma Leuk , vol.11 , Issue.1 , pp. 136-138
    • Rossi, J.F.1
  • 61
    • 0038386032 scopus 로고    scopus 로고
    • Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
    • Lentzsch S., Gries M., Janz M., Bargou R., Dorken B., Mapara M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003, 101:3568-3573.
    • (2003) Blood , vol.101 , pp. 3568-3573
    • Lentzsch, S.1    Gries, M.2    Janz, M.3    Bargou, R.4    Dorken, B.5    Mapara, M.Y.6
  • 62
    • 0035383761 scopus 로고    scopus 로고
    • Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand
    • Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., Roodman G.D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97:3349-3353.
    • (2001) Blood , vol.97 , pp. 3349-3353
    • Han, J.H.1    Choi, S.J.2    Kurihara, N.3    Koide, M.4    Oba, Y.5    Roodman, G.D.6
  • 63
    • 0141707692 scopus 로고    scopus 로고
    • Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma
    • Terpos E., Politou M., Szydlo R., Goldman J.M., Apperley J.F., Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003, 123(1):106-109.
    • (2003) Br J Haematol , vol.123 , Issue.1 , pp. 106-109
    • Terpos, E.1    Politou, M.2    Szydlo, R.3    Goldman, J.M.4    Apperley, J.F.5    Rahemtulla, A.6
  • 64
    • 70450245348 scopus 로고    scopus 로고
    • Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
    • Roussou M., Tasidou A., Dimopoulos M.A., et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009, 23(11):2177-2181.
    • (2009) Leukemia , vol.23 , Issue.11 , pp. 2177-2181
    • Roussou, M.1    Tasidou, A.2    Dimopoulos, M.A.3
  • 65
    • 0038579121 scopus 로고    scopus 로고
    • Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
    • Oyajobi B.O., Franchin G., Williams P.J., et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003, 102:311-319.
    • (2003) Blood , vol.102 , pp. 311-319
    • Oyajobi, B.O.1    Franchin, G.2    Williams, P.J.3
  • 66
    • 36348988548 scopus 로고    scopus 로고
    • MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
    • Vallet S., Raje N., Ishitsuka K., et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110:3744-3752.
    • (2007) Blood , vol.110 , pp. 3744-3752
    • Vallet, S.1    Raje, N.2    Ishitsuka, K.3
  • 67
    • 0034676060 scopus 로고    scopus 로고
    • Decreased c-Src expression enhances osteoblast differentiation and bone formation
    • Marzia M., Sims N.A., Voit S., et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000, 151(2):311-320.
    • (2000) J Cell Biol , vol.151 , Issue.2 , pp. 311-320
    • Marzia, M.1    Sims, N.A.2    Voit, S.3
  • 69
    • 0037150728 scopus 로고    scopus 로고
    • Src in cancer: deregulation and consequences for cell behaviour
    • Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602(2):114-130.
    • (2002) Biochim Biophys Acta , vol.1602 , Issue.2 , pp. 114-130
    • Frame, M.C.1
  • 70
    • 79951499354 scopus 로고    scopus 로고
    • Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo
    • Dai Y., Chen S., Shah R., et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011, 117(6):1947-1957.
    • (2011) Blood , vol.117 , Issue.6 , pp. 1947-1957
    • Dai, Y.1    Chen, S.2    Shah, R.3
  • 71
    • 51649116942 scopus 로고    scopus 로고
    • Validation of PDGFR beta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
    • Coluccia A.M., Cirulli T., Neri P., et al. Validation of PDGFR beta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112(4):1346-1356.
    • (2008) Blood , vol.112 , Issue.4 , pp. 1346-1356
    • Coluccia, A.M.1    Cirulli, T.2    Neri, P.3
  • 72
    • 77952292726 scopus 로고    scopus 로고
    • Effect of dasatinib on bone metabolism in multiple myeloma
    • Wildes T.M., Procknow E., Weilbaecher K., Vij R. Effect of dasatinib on bone metabolism in multiple myeloma. J Clin Oncol 2008, 26(Suppl. 20):8568.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 20 , pp. 8568
    • Wildes, T.M.1    Procknow, E.2    Weilbaecher, K.3    Vij, R.4
  • 73
    • 84861714290 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT01116128.
  • 76
    • 77954132791 scopus 로고    scopus 로고
    • Osteoclast-specific Inactivation of the integrin-linked kinase (ILK) inhibits bone resorption
    • Dossa T., Arabian A., Windle J., et al. Osteoclast-specific Inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem 2010, 110(4):960-967.
    • (2010) J Cell Biochem , vol.110 , Issue.4 , pp. 960-967
    • Dossa, T.1    Arabian, A.2    Windle, J.3
  • 77
    • 33846188062 scopus 로고    scopus 로고
    • Direct Targeting of avb3 integrin on tumor cells
    • Mulgrew K., Kinneer K., Yao X.T., et al. Direct Targeting of avb3 integrin on tumor cells. Mol Cancer Ther 2006, 5:3122-3129.
    • (2006) Mol Cancer Ther , vol.5 , pp. 3122-3129
    • Mulgrew, K.1    Kinneer, K.2    Yao, X.T.3
  • 79
    • 77952544910 scopus 로고    scopus 로고
    • New treatment targets in osteoporosis
    • Roux S. New treatment targets in osteoporosis. Joint Bone Spine 2010, 7(3):222-228.
    • (2010) Joint Bone Spine , vol.7 , Issue.3 , pp. 222-228
    • Roux, S.1
  • 80
    • 0036780593 scopus 로고    scopus 로고
    • The role of the integrin avb3 in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?
    • Teti A., Migliaccio S., Baron R. The role of the integrin avb3 in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?. Calcif Tissue Int 2002, 71(4):293-299.
    • (2002) Calcif Tissue Int , vol.71 , Issue.4 , pp. 293-299
    • Teti, A.1    Migliaccio, S.2    Baron, R.3
  • 81
    • 27244441444 scopus 로고    scopus 로고
    • Functional osteoclast-like transformation of cultured human myeloma cell lines
    • Calvani N., Cafforio P., Silvestris F., Dammacco F. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 2005, 130(6):926-938.
    • (2005) Br J Haematol , vol.130 , Issue.6 , pp. 926-938
    • Calvani, N.1    Cafforio, P.2    Silvestris, F.3    Dammacco, F.4
  • 82
    • 39049101272 scopus 로고    scopus 로고
    • Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro
    • Silvestris F., Cafforio P., De Matteo M., Quatraro C., Dammacco F. Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 2008, 32(4):611-623.
    • (2008) Leuk Res , vol.32 , Issue.4 , pp. 611-623
    • Silvestris, F.1    Cafforio, P.2    De Matteo, M.3    Quatraro, C.4    Dammacco, F.5
  • 83
    • 69249134137 scopus 로고    scopus 로고
    • Beta3 subunit integrin mediates the bone-resorbing function exerted by cultured myeloma plasma cells
    • Tucci M., De Palma R., Lombardi L., et al. Beta3 subunit integrin mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009, 69(16):6738-6746.
    • (2009) Cancer Res , vol.69 , Issue.16 , pp. 6738-6746
    • Tucci, M.1    De Palma, R.2    Lombardi, L.3
  • 84
    • 77951678924 scopus 로고    scopus 로고
    • Blockade of the MEK/ERKsignalling cascade by AS703026, a novel selective MEK 1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
    • Kim K., Kong S.Y., Fulciniti M., et al. Blockade of the MEK/ERKsignalling cascade by AS703026, a novel selective MEK 1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010, 149(4):537-549.
    • (2010) Br J Haematol , vol.149 , Issue.4 , pp. 537-549
    • Kim, K.1    Kong, S.Y.2    Fulciniti, M.3
  • 85
    • 34548844157 scopus 로고    scopus 로고
    • Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
    • Tai Y.T., Fulciniti M., Hideshima T., et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007, 110(5):1656-1663.
    • (2007) Blood , vol.110 , Issue.5 , pp. 1656-1663
    • Tai, Y.T.1    Fulciniti, M.2    Hideshima, T.3
  • 86
    • 79952123613 scopus 로고    scopus 로고
    • A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
    • Annunziata C.M., Hernandez L., Davis R.E., et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011, 117(8):2396-2404.
    • (2011) Blood , vol.117 , Issue.8 , pp. 2396-2404
    • Annunziata, C.M.1    Hernandez, L.2    Davis, R.E.3
  • 87
    • 84861690918 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT01085214.
  • 88
    • 0034613188 scopus 로고    scopus 로고
    • Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)
    • Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000, 275(40):55-61.
    • (2000) J Biol Chem , vol.275 , Issue.40 , pp. 55-61
    • Matsumoto, M.1    Sudo, T.2    Saito, T.3    Osada, H.4    Tsujimoto, M.5
  • 89
    • 58149154965 scopus 로고    scopus 로고
    • P38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma
    • Medicherla S., Reddy M., Ying J., et al. P38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res 2008, 28(6A):3827-3833.
    • (2008) Anticancer Res , vol.28 , Issue.6 A , pp. 3827-3833
    • Medicherla, S.1    Reddy, M.2    Ying, J.3
  • 90
    • 34250328203 scopus 로고    scopus 로고
    • Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma
    • Vanderkerken K., Medicherla S., Coulton L., et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res 2007, 67(10):4572-4577.
    • (2007) Cancer Res , vol.67 , Issue.10 , pp. 4572-4577
    • Vanderkerken, K.1    Medicherla, S.2    Coulton, L.3
  • 91
    • 43449140012 scopus 로고    scopus 로고
    • P38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
    • Ishitsuka K., Hideshima T., Neri P., et al. P38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008, 141(5):598-606.
    • (2008) Br J Haematol , vol.141 , Issue.5 , pp. 598-606
    • Ishitsuka, K.1    Hideshima, T.2    Neri, P.3
  • 92
    • 33744494283 scopus 로고    scopus 로고
    • Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
    • Navas T.A., Nguyen A.N., Hideshima T., et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006, 20(6):1017-1027.
    • (2006) Leukemia , vol.20 , Issue.6 , pp. 1017-1027
    • Navas, T.A.1    Nguyen, A.N.2    Hideshima, T.3
  • 93
    • 84861714291 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT01393990.
  • 94
    • 33644644120 scopus 로고    scopus 로고
    • Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    • Ge Y., Zhan F., Barlogie B., Epstein J., Shaughnessy J., Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 2006, 133(1):83-92.
    • (2006) Br J Haematol , vol.133 , Issue.1 , pp. 83-92
    • Ge, Y.1    Zhan, F.2    Barlogie, B.3    Epstein, J.4    Shaughnessy, J.5    Yaccoby, S.6
  • 95
    • 66849104453 scopus 로고    scopus 로고
    • Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
    • Pennisi A., Li X., Ling W., et al. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol 2009, 145(6):775-787.
    • (2009) Br J Haematol , vol.145 , Issue.6 , pp. 775-787
    • Pennisi, A.1    Li, X.2    Ling, W.3
  • 96
    • 59649086503 scopus 로고    scopus 로고
    • SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
    • Okawa Y., Hideshima T., Steed P., et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113(4):846-855.
    • (2009) Blood , vol.113 , Issue.4 , pp. 846-855
    • Okawa, Y.1    Hideshima, T.2    Steed, P.3
  • 97
    • 0043267732 scopus 로고    scopus 로고
    • Genetic regulation of osteoclast development and function
    • Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4(8):638-649.
    • (2003) Nat Rev Genet , vol.4 , Issue.8 , pp. 638-649
    • Teitelbaum, S.L.1    Ross, F.P.2
  • 98
    • 0032506007 scopus 로고    scopus 로고
    • Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice
    • Saftig P., Hunziker E., Wehmeyer O., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998, 95(23):13453-13458.
    • (1998) Proc Natl Acad Sci USA , vol.95 , Issue.23 , pp. 13453-13458
    • Saftig, P.1    Hunziker, E.2    Wehmeyer, O.3
  • 99
    • 80051471238 scopus 로고    scopus 로고
    • Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
    • Costa A.G., Cusano N.E., Silva B.C., Cremers S., Bilezikian J.P. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011, 7(8):447-456.
    • (2011) Nat Rev Rheumatol , vol.7 , Issue.8 , pp. 447-456
    • Costa, A.G.1    Cusano, N.E.2    Silva, B.C.3    Cremers, S.4    Bilezikian, J.P.5
  • 100
    • 71249086491 scopus 로고    scopus 로고
    • Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial
    • Jensen A.B., Wynne C., Ramirez G., et al. Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol 2008, 26(Suppl. 1):1023.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 1 , pp. 1023
    • Jensen, A.B.1    Wynne, C.2    Ramirez, G.3
  • 101
    • 80052279445 scopus 로고    scopus 로고
    • The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking
    • Leung P., Pickarski M., Zhuo Y., Masarachia P.J., Duong L.T. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011, 49(4):623-635.
    • (2011) Bone , vol.49 , Issue.4 , pp. 623-635
    • Leung, P.1    Pickarski, M.2    Zhuo, Y.3    Masarachia, P.J.4    Duong, L.T.5
  • 102
    • 54249131123 scopus 로고    scopus 로고
    • VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin
    • Yang Q., McHugh K.P., Patntirapong S., Gu X., Wunderlich L., Hauschka P.V. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 2008, 27(7):589-599.
    • (2008) Matrix Biol , vol.27 , Issue.7 , pp. 589-599
    • Yang, Q.1    McHugh, K.P.2    Patntirapong, S.3    Gu, X.4    Wunderlich, L.5    Hauschka, P.V.6
  • 103
    • 1542782290 scopus 로고    scopus 로고
    • RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism
    • Henriksen K., Karsdal M., Delaisse J.M., Engsig M.T. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003, 278(49):48745-48753.
    • (2003) J Biol Chem , vol.278 , Issue.49 , pp. 48745-48753
    • Henriksen, K.1    Karsdal, M.2    Delaisse, J.M.3    Engsig, M.T.4
  • 104
    • 33847368961 scopus 로고    scopus 로고
    • Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin
    • Tanaka Y., Abe M., Hiasa M., et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007, 13(3):816-823.
    • (2007) Clin Cancer Res , vol.13 , Issue.3 , pp. 816-823
    • Tanaka, Y.1    Abe, M.2    Hiasa, M.3
  • 105
    • 45549086020 scopus 로고    scopus 로고
    • Link between osteoclastogenesis, angiogenesis and myeloma expansion
    • Abe M. Link between osteoclastogenesis, angiogenesis and myeloma expansion. Clin Calcium 2008, 18(4):473-479.
    • (2008) Clin Calcium , vol.18 , Issue.4 , pp. 473-479
    • Abe, M.1
  • 106
    • 84861714287 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00428545.
  • 107
    • 84861691452 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00410605.
  • 108
    • 33845193025 scopus 로고    scopus 로고
    • Myeloma bone disease: pathogenetic mechanisms and clinical assessment
    • Silvestris F., Lombardi L., De Matteo M., Bruno A., Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 2007, 31(2):129-138.
    • (2007) Leuk Res , vol.31 , Issue.2 , pp. 129-138
    • Silvestris, F.1    Lombardi, L.2    De Matteo, M.3    Bruno, A.4    Dammacco, F.5
  • 109
    • 34548128339 scopus 로고    scopus 로고
    • The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    • Terpos E., Dimopoulos M.A., Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007, 21:1875-1884.
    • (2007) Leukemia , vol.21 , pp. 1875-1884
    • Terpos, E.1    Dimopoulos, M.A.2    Sezer, O.3
  • 110
    • 78650305162 scopus 로고    scopus 로고
    • Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth
    • Takeuchi K., Abe M., et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. Plos one 2010, 5(3):e9870.
    • (2010) Plos one , vol.5 , Issue.3
    • Takeuchi, K.1    Abe, M.2
  • 111
    • 76349110797 scopus 로고    scopus 로고
    • Osteoblastogenesis and tumor growth in myeloma
    • Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010, 51(2):213-220.
    • (2010) Leuk Lymphoma , vol.51 , Issue.2 , pp. 213-220
    • Yaccoby, S.1
  • 112
    • 47249093295 scopus 로고    scopus 로고
    • Role of decorin in the antimyeloma effects of osteoblasts
    • Li X., Pennisi A., Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008, 112(1):159-168.
    • (2008) Blood , vol.112 , Issue.1 , pp. 159-168
    • Li, X.1    Pennisi, A.2    Yaccoby, S.3
  • 113
    • 13444302715 scopus 로고    scopus 로고
    • Sequential roles of Hedgehog and Wnt signaling in osteoblast development
    • Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005, 132(1):49-60.
    • (2005) Development , vol.132 , Issue.1 , pp. 49-60
    • Hu, H.1    Hilton, M.J.2    Tu, X.3    Yu, K.4    Ornitz, D.M.5    Long, F.6
  • 114
    • 0038783316 scopus 로고    scopus 로고
    • Secreted antagonists of the Wnt signalling pathway
    • Kawano Y., Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116(Pt 13):2627-2634.
    • (2003) J Cell Sci , vol.116 , Issue.PART 13 , pp. 2627-2634
    • Kawano, Y.1    Kypta, R.2
  • 115
    • 33847397091 scopus 로고    scopus 로고
    • Antibody based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    • Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109(5):2106-2111.
    • (2007) Blood , vol.109 , Issue.5 , pp. 2106-2111
    • Yaccoby, S.1    Ling, W.2    Zhan, F.3    Walker, R.4    Barlogie, B.5    Shaughnessy, J.D.6
  • 116
    • 67650431302 scopus 로고    scopus 로고
    • Anti DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
    • Fulciniti M., Tassone P., Hideshima T., et al. Anti DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114(2):371-379.
    • (2009) Blood , vol.114 , Issue.2 , pp. 371-379
    • Fulciniti, M.1    Tassone, P.2    Hideshima, T.3
  • 117
    • 84861691451 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00741377.
  • 118
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
    • (2001) N Engl J Med , vol.344 , Issue.19 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 119
    • 80054893464 scopus 로고    scopus 로고
    • Parathyroid hormone analogues in the treatment of osteoporosis
    • Kraenzlin M.E., Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 2011 Jul 12, 7(11):647-656.
    • (2011) Nat Rev Endocrinol , vol.7 , Issue.11 , pp. 647-656
    • Kraenzlin, M.E.1    Meier, C.2
  • 120
    • 80054002136 scopus 로고    scopus 로고
    • Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials
    • Shen L., Xie X., Su Y., Luo C., Zhang C., Zeng B. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One 2011, 6(10):e26267.
    • (2011) PLoS One , vol.6 , Issue.10
    • Shen, L.1    Xie, X.2    Su, Y.3    Luo, C.4    Zhang, C.5    Zeng, B.6
  • 121
    • 26844521277 scopus 로고    scopus 로고
    • Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis
    • Bellido T., Ali A.A., Gubrij I., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146(11):4577-4583.
    • (2005) Endocrinology , vol.146 , Issue.11 , pp. 4577-4583
    • Bellido, T.1    Ali, A.A.2    Gubrij, I.3
  • 122
    • 0033577851 scopus 로고    scopus 로고
    • Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation
    • Serra R., Karaplis A., Sohn P. Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J Cell Biol 1999, 145(4):783-794.
    • (1999) J Cell Biol , vol.145 , Issue.4 , pp. 783-794
    • Serra, R.1    Karaplis, A.2    Sohn, P.3
  • 123
    • 47849098824 scopus 로고    scopus 로고
    • EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts
    • Allan E.H., Häusler K.D., Wei T., et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. TJ J Bone Miner Res 2008, 23(8):1170-1181.
    • (2008) TJ J Bone Miner Res , vol.23 , Issue.8 , pp. 1170-1181
    • Allan, E.H.1    Häusler, K.D.2    Wei, T.3
  • 124
    • 60849137479 scopus 로고    scopus 로고
    • Endogenous FGF-2 is critically important in PTH anabolic effects on bone
    • Sabbieti M.G., Agas D., Xiao L., et al. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 2009, 219(1):143-151.
    • (2009) J Cell Physiol , vol.219 , Issue.1 , pp. 143-151
    • Sabbieti, M.G.1    Agas, D.2    Xiao, L.3
  • 125
    • 78650875646 scopus 로고    scopus 로고
    • Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
    • Pennisi A., Ling W., Li X., et al. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One 2010, 5(12):e15233.
    • (2010) PLoS One , vol.5 , Issue.12
    • Pennisi, A.1    Ling, W.2    Li, X.3
  • 126
    • 77954505723 scopus 로고    scopus 로고
    • Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice
    • Weinstein R.S., Jilka R.L., Almeida M., Roberson P.K., Manolagas S.C. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010, 151(6):2641-2649.
    • (2010) Endocrinology , vol.151 , Issue.6 , pp. 2641-2649
    • Weinstein, R.S.1    Jilka, R.L.2    Almeida, M.3    Roberson, P.K.4    Manolagas, S.C.5
  • 127
    • 36148958951 scopus 로고    scopus 로고
    • Teriparatide or alendronate in glucocorticoid-induced osteoporosis
    • Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357(20):2028-2039.
    • (2007) N Engl J Med , vol.357 , Issue.20 , pp. 2028-2039
    • Saag, K.G.1    Shane, E.2    Boonen, S.3
  • 128
    • 70350555320 scopus 로고    scopus 로고
    • Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial
    • Saag K.G., Zanchetta J.R., Devogelaer J.P., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60(11):3346-3355.
    • (2009) Arthritis Rheum , vol.60 , Issue.11 , pp. 3346-3355
    • Saag, K.G.1    Zanchetta, J.R.2    Devogelaer, J.P.3
  • 129
    • 73649100585 scopus 로고    scopus 로고
    • Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis
    • Devogelaer J.P., Adler R.A., Recknor C., et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010, 37(1):141-148.
    • (2010) J Rheumatol , vol.37 , Issue.1 , pp. 141-148
    • Devogelaer, J.P.1    Adler, R.A.2    Recknor, C.3
  • 130
    • 65349134769 scopus 로고    scopus 로고
    • Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone
    • Mohammad K.S., Chen C.G., Balooch G., et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009, 4(4):e5275.
    • (2009) PLoS One , vol.4 , Issue.4
    • Mohammad, K.S.1    Chen, C.G.2    Balooch, G.3
  • 131
    • 78650307123 scopus 로고    scopus 로고
    • TGF-β-related mechanisms of bone destruction in multiple myeloma
    • Matsumoto T., Abe M. TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone 2011, 48(1):129-134.
    • (2011) Bone , vol.48 , Issue.1 , pp. 129-134
    • Matsumoto, T.1    Abe, M.2
  • 132
    • 78650305162 scopus 로고    scopus 로고
    • Tgf-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth
    • Takeuchi K., Abe M., Hiasa M., et al. Tgf-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 2010, 5(3):e9870.
    • (2010) PLoS One , vol.5 , Issue.3
    • Takeuchi, K.1    Abe, M.2    Hiasa, M.3
  • 133
    • 84859631972 scopus 로고    scopus 로고
    • Sclerostin: a novel target for intervention in the treatment of osteoporosis
    • Lewiecki E.M. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med 2011, 12(65):263-273.
    • (2011) Discov Med , vol.12 , Issue.65 , pp. 263-273
    • Lewiecki, E.M.1
  • 134
    • 84864144433 scopus 로고    scopus 로고
    • Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction post-bortezomib monotherapy
    • Terpos E., Christoulas D., Katodritou E., et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction post-bortezomib monotherapy. Int J Cancer 2011 Nov 2, 10.1002/ijc.27342.
    • (2011) Int J Cancer
    • Terpos, E.1    Christoulas, D.2    Katodritou, E.3
  • 135
    • 0034607068 scopus 로고    scopus 로고
    • Activin A is an essential cofactor for osteoclast induction
    • Fuller K., Bayley K.E., Chambers T.J. Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 2000, 268(1):2-7.
    • (2000) Biochem Biophys Res Commun , vol.268 , Issue.1 , pp. 2-7
    • Fuller, K.1    Bayley, K.E.2    Chambers, T.J.3
  • 136
    • 77950438331 scopus 로고    scopus 로고
    • Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
    • Vallet S., Mukherjee S., Vaghela N., et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Nat Acad Sci USA 2010, 107(11):5124-5129.
    • (2010) Proc Nat Acad Sci USA , vol.107 , Issue.11 , pp. 5124-5129
    • Vallet, S.1    Mukherjee, S.2    Vaghela, N.3
  • 137
    • 65549147617 scopus 로고    scopus 로고
    • Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgGl) in postmenopausal women
    • Ruckle J., Jacobs M., Kramer W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgGl) in postmenopausal women. J Bone Miner Res 2009, 24(4):744-752.
    • (2009) J Bone Miner Res , vol.24 , Issue.4 , pp. 744-752
    • Ruckle, J.1    Jacobs, M.2    Kramer, W.3
  • 138
    • 77956555237 scopus 로고    scopus 로고
    • ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis
    • Abdulkadyrov K.M., Salogub G.N., Khuazheva N.K., et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis. Blood 2009, 114:749.
    • (2009) Blood , vol.114 , pp. 749
    • Abdulkadyrov, K.M.1    Salogub, G.N.2    Khuazheva, N.K.3
  • 139
    • 0037097595 scopus 로고    scopus 로고
    • Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    • Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
    • (2002) Blood , vol.99 , pp. 4525-4530
    • Mitsiades, N.1    Mitsiades, C.S.2    Poulaki, V.3
  • 140
    • 0037262242 scopus 로고    scopus 로고
    • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
    • Lentzsch S., LeBlanc R., Podar K., et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003, 17(1):41-44.
    • (2003) Leukemia , vol.17 , Issue.1 , pp. 41-44
    • Lentzsch, S.1    LeBlanc, R.2    Podar, K.3
  • 141
    • 33645736007 scopus 로고    scopus 로고
    • Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
    • Anderson G., Gries M., Kurihara N., et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107(8):3098-3105.
    • (2006) Blood , vol.107 , Issue.8 , pp. 3098-3105
    • Anderson, G.1    Gries, M.2    Kurihara, N.3
  • 142
    • 54049156803 scopus 로고    scopus 로고
    • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    • Breitkreutz I., Raab M.S., Vallet S., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22(10):1925-1932.
    • (2008) Leukemia , vol.22 , Issue.10 , pp. 1925-1932
    • Breitkreutz, I.1    Raab, M.S.2    Vallet, S.3
  • 143
    • 2342613652 scopus 로고    scopus 로고
    • The proteasome: a suitable antineoplastic target
    • Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4(5):349-360.
    • (2004) Nat Rev Cancer , vol.4 , Issue.5 , pp. 349-360
    • Adams, J.1
  • 144
    • 0036009115 scopus 로고    scopus 로고
    • NF-kappaB at the crossroads of life and death
    • Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3(3):221-227.
    • (2002) Nat Immunol , vol.3 , Issue.3 , pp. 221-227
    • Karin, M.1    Lin, A.2
  • 145
    • 34548133601 scopus 로고    scopus 로고
    • Bortezomib inhibits human osteoclastogenesis
    • von Metzler I., Krebbel H., Hecht M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007, 21(9):2025-2034.
    • (2007) Leukemia , vol.21 , Issue.9 , pp. 2025-2034
    • von Metzler, I.1    Krebbel, H.2    Hecht, M.3
  • 146
    • 34548029349 scopus 로고    scopus 로고
    • Myeloma bone disease and proteasome inhibition therapies
    • Terpos E., Sezer O., Croucher P., Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110(4):1098-1104.
    • (2007) Blood , vol.110 , Issue.4 , pp. 1098-1104
    • Terpos, E.1    Sezer, O.2    Croucher, P.3    Dimopoulos, M.A.4
  • 147
    • 33751193178 scopus 로고    scopus 로고
    • Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
    • Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108(13):3992-3996.
    • (2006) Blood , vol.108 , Issue.13 , pp. 3992-3996
    • Giuliani, N.1    Rizzoli, V.2    Roodman, G.D.3
  • 148
    • 66149127277 scopus 로고    scopus 로고
    • Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling
    • Qiang Y.W., Hu B., Chen Y., et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009, 113(18):4319-4330.
    • (2009) Blood , vol.113 , Issue.18 , pp. 4319-4330
    • Qiang, Y.W.1    Hu, B.2    Chen, Y.3
  • 149
    • 20844451019 scopus 로고    scopus 로고
    • High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation
    • Shimazaki C., Uchida R., Nakano S., et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 2005, 19(6):1102-1103.
    • (2005) Leukemia , vol.19 , Issue.6 , pp. 1102-1103
    • Shimazaki, C.1    Uchida, R.2    Nakano, S.3
  • 150
    • 79551627290 scopus 로고    scopus 로고
    • A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
    • Zangari M., Yaccoby S., Pappas L., et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011, 96(2):333-336.
    • (2011) Haematologica , vol.96 , Issue.2 , pp. 333-336
    • Zangari, M.1    Yaccoby, S.2    Pappas, L.3
  • 151
    • 34347400592 scopus 로고    scopus 로고
    • The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
    • Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110(1):334-338.
    • (2007) Blood , vol.110 , Issue.1 , pp. 334-338
    • Giuliani, N.1    Morandi, F.2    Tagliaferri, S.3
  • 152
    • 70350212674 scopus 로고    scopus 로고
    • Mesenchymal stem cells for bone repair and metabolic bone diseases
    • Anita H., Westendorf Jennifer J., Yaszemski Michael J., Khosla Sundeep Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 2009, 84(10):893-902.
    • (2009) Mayo Clin Proc , vol.84 , Issue.10 , pp. 893-902
    • Anita, H.1    Westendorf, J.J.2    Yaszemski, M.J.3    Khosla, S.4
  • 153
    • 19944426620 scopus 로고    scopus 로고
    • Isolation of multipotent cells from human term placenta
    • Yen B.L., Huang H.I., Chien C.C. Isolation of multipotent cells from human term placenta. Stem Cells 2005, 23(1):3-9.
    • (2005) Stem Cells , vol.23 , Issue.1 , pp. 3-9
    • Yen, B.L.1    Huang, H.I.2    Chien, C.C.3
  • 154
    • 0032976690 scopus 로고    scopus 로고
    • Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
    • Horwitz E.M., Prockop D.J., Fitzpatrick L.A., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5(3):309-313.
    • (1999) Nat Med , vol.5 , Issue.3 , pp. 309-313
    • Horwitz, E.M.1    Prockop, D.J.2    Fitzpatrick, L.A.3
  • 155
    • 79952151635 scopus 로고    scopus 로고
    • Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    • Li X., Ling W., Pennisi A., et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells 2011, 29(2):263-273.
    • (2011) Stem Cells , vol.29 , Issue.2 , pp. 263-273
    • Li, X.1    Ling, W.2    Pennisi, A.3
  • 156
    • 57449102937 scopus 로고    scopus 로고
    • Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells
    • Barlow S., Brooke G., Chatterjee K., et al. Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008, 17(6):1095-1107.
    • (2008) Stem Cells Dev , vol.17 , Issue.6 , pp. 1095-1107
    • Barlow, S.1    Brooke, G.2    Chatterjee, K.3
  • 157
    • 84861714282 scopus 로고    scopus 로고
    • 3rd. Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? Stem Cells.
    • Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd. Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? Stem Cells. 2010.
    • (2010)
    • Klopp, A.H.1    Gupta, A.2    Spaeth, E.3    Andreeff, M.4    Marini, F.5
  • 158
    • 33947197883 scopus 로고    scopus 로고
    • Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells
    • Bhardwaj A., Sethi G., Vadhan-Raj S., et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109(6):2293-2302.
    • (2007) Blood , vol.109 , Issue.6 , pp. 2293-2302
    • Bhardwaj, A.1    Sethi, G.2    Vadhan-Raj, S.3
  • 159
    • 27544495989 scopus 로고    scopus 로고
    • Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation
    • Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaissé J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005, 65(21):9943-9952.
    • (2005) Cancer Res , vol.65 , Issue.21 , pp. 9943-9952
    • Boissy, P.1    Andersen, T.L.2    Abdallah, B.M.3    Kassem, M.4    Plesner, T.5    Delaissé, J.M.6
  • 160
    • 0034130860 scopus 로고    scopus 로고
    • Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats
    • Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 2000, 46(2):78-83.
    • (2000) J Nutr Sci Vitaminol (Tokyo) , vol.46 , Issue.2 , pp. 78-83
    • Mizutani, K.1    Ikeda, K.2    Kawai, Y.3    Yamori, Y.4
  • 161
    • 18144380684 scopus 로고    scopus 로고
    • Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model
    • Liu Z.P., Li Wx., Yu B. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J Med Food 2005, 8(1):14-19.
    • (2005) J Med Food , vol.8 , Issue.1 , pp. 14-19
    • Liu, Z.P.1    Li, W.2    Yu, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.